Drugs -- Dosage forms -- Research -- United StatesSee also what's at your library, or elsewhere.
Broader terms: |
Filed under: Drugs -- Dosage forms -- Research -- United States
Items below (if any) are from related and broader terms.
Filed under: Drugs -- Dosage forms -- United States -- Evaluation Federal and state role in pharmacy compounding and reconstitution : exploring the right mix to protect patients : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, first session, on examining state and federal oversight to ensure the safety and quality of drug compounding--the process of mixing, combining, or altering ingredients to create a customized medication for an individual patient--by pharmacies, October 23, 2003. (U.S. G.P.O. :, 2004), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust) Filed under: Drugs -- Dosage forms -- United States -- Indexes
Filed under: Drugs -- Research -- United States Pharmaceutical R&D: Costs, Risks, and Rewards (OTA-H-522; 1993), by United States Congress Office of Technology Assessment (page images at HathiTrust) Final report (Dept. of Health, Education, and Welfare, 1977), by Education United States. Department of Health (page images at HathiTrust) Assessment of the Commissioner's report of October 1975 (The Department, 1976), by Education United States. Department of Health (page images at HathiTrust) The Commissioner's report of investigation of charges from joint hearings, Subcommittee on Health, Labor and Public Welfare Committee, Subcommittee on Administrative Practice and Procedure, Judiciary Committee, United States Senate, August 15-16, 1974. ([Food and Drug Administration?], 1975), by United States Food and Drug Administration and Alexander M. Schmidt (page images at HathiTrust) Medicines by design : the biological revolution in pharmacology. (U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health :, 1993), by National Institute of General Medical Sciences (U.S.). Office of Research Reports and National Institute of General Medical Sciences (U.S.) (page images at HathiTrust) Pharmaceutical innovation--promises and problems hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment and the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, April 27, 1981. (U.S. G.P.O., 1982), by Agriculture Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources and United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight (page images at HathiTrust) How health care reform affects pharmaceutical research and development (The Office, 1994), by Anna Cook, Philip Webre, and United States Congressional Budget Office (page images at HathiTrust) Preclinical and clinical testing by the pharmaceutical industry, 1976 joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, second session, on examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out ... (U.S. Govt. Print. Off., 1976), by United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health and United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Administrative Practice and Procedure (page images at HathiTrust) Biological testing involving human subjects by the Department of Defense, 1977 hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ... March 8 and May 23, 1977. (U.S. Govt. Print. Off., 1977), by United State Senate Subcommittee on Health and Scientific Research (page images at HathiTrust) Preclinical and clinical testing by the pharmaceutical industry, 1977 hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ... (U.S. Govt. Print. Off., 1977), by United State Senate Subcommittee on Health and Scientific Research, United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Administrative Practice and Procedure, and United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health (page images at HathiTrust) The Food and Drug Administration's process for approving new drugs : report (U.S. G.P.O. :, 1980), by Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Science (page images at HathiTrust) New drug development in the United States (Dept. of Health & Human Services, Public Health Service, Food and Drug Administration, 1995), by United States Food and Drug Administration (page images at HathiTrust) Contrary to allegation, NIH hydrazine suflfate studies were not flawed, report to the Chairman (The Office ;, 1995), by United States General Accounting Office and United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations (page images at HathiTrust) Medical devices : FDA's 510(k) operations could be improved : report to the chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representative (The Office, 1988), by United States General Accounting Office and United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust) Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Tenth Congress, first session, special hearing, June 1, 2007, Salt Lake City, Utah. (U.S. G.P.O. :, 2008), by Rural Development United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture (page images at HathiTrust) Structure-activity relationships of the cannabinoids (U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse ;, 1987), by Alexandros Makriyannis, Rao S. Rapaka, and National Institute on Drug Abuse (page images at HathiTrust) From test tube to patient : new drug development in the United States. (Dept. of Health & Human Services, Public Health Service, Food and Drug Administration, 1990), by United States Food and Drug Administration (page images at HathiTrust) U.S. pharmaceutical research and development, and its impact on women's health : the technology deficit in contraception, cancer, and reproductive disease and conditions : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Camden, NJ, May 8, 1992. (Washington : U.S. G.P.O. : For slae by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1992., 1992), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust) New drug evaluation : statistical report ([Rockville, Md.] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drugs and Biologics, Office of Management ;, 1987), by United States. National Technical Information Service (page images at HathiTrust) Federal control of new drug testing is not adequately protecting human test subjects and the public, Food and Drug Administration, Department of Health, Education, and Welfare : report to the Congress (U.S. General Accounting Office, 1976), by United States General Accounting Office (page images at HathiTrust) Biological testing involving human subjects by the Department of Defense, 1977 : hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ... March 8 and May 23, 1977. (U.S. Govt. Print. Off. :, 1977), by United State Senate Subcommittee on Health and Scientific Research (page images at HathiTrust) Obstacles to drug development for HIV-related opportunistic infections : seventh report (U.S. G.P.O., 1991), by United States House Committee on Government Operations (page images at HathiTrust) Interagency Coordination in Drug Research and Regulation : hearings before the United States Senate Committee on Government Operations, Subcommittee on Reorganization and International Organizations, Eighty-Seventh and Eighty-Eighth Congresses. (U.S. G.P.O., 1963), by United States. Congress. Senate. Committee on Government Operations. Subcommittee on Reorganization and International Organizations (page images at HathiTrust) Preclinical and clinical testing by the pharmaceutical industry, 1976 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, second session, on examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out. (U.S. Govt. Print. Off, 1975), by United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health and United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Administrative Practice and Procedure (page images at HathiTrust) Antibiotic resistance and the threat to public health : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, April 28, 2010. (Washington, DC : For sale by the Superintendent of Documents, U.S. G.P.O., 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust) The controlled substances act of 1970: a BNDD manual for researchers. (Washington, D.C. :, 1971), by United States. Bureau of Narcotics and Dangerous Drugs. Office of Scientific Support (page images at HathiTrust) Summary of the report of the Advisory Review Panel (Dept. of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, Office of Public Affairs, 1977), by Antipyretic United States. Food and Drug Administration. Advisory Review Panel on OTC Internal Analgesic and United States Food and Drug Administration (page images at HathiTrust) Diethylstilbestrol (DES) drug controversy ([Washington, D.C.] : Library of Congress, Congressional Research Service, Major Issues System, [1980], 1980), by Sarah L. Hartman and Library of Congress. Congressional Research Service (page images at HathiTrust) Pharmacology Research Associate Program, The National Institutes of Health, Sponsored by: The Pharmacology-Toxicology Program, The National Institute of General Medical Sciences. (United States Government Printing Office, 1978), by National Institutes of Health (U.S.), Sara A. Gardner, and United States Department of Health, Education, and Welfare (page images at HathiTrust) Pharmacology Research Associate Program of the National Institutes of Health (National Institute of General Medical Sciences, 1975), by National Institute of General Medical Sciences (U.S.), Sara A. Gardner, Byron B. Clark, and United States Department of Health, Education, and Welfare (page images at HathiTrust) Pharmacology Research Associate Program, The National Institutes of Health, Sponsored by The Pharmacology-Toxicology Program, The National Institute of General Medical Sciences. (Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Institute of General Medical Sciences, 1977), by National Institute of General Medical Sciences (U.S.), Sara A. Gardner, Byron B. Clark, and United States Department of Health, Education, and Welfare (page images at HathiTrust) Preclinical and clinical testing by the pharmaceutical industry, 1975 : joint Hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare, and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, first session- (U.S. Govt. Print. Off., 1975), by United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health and United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Administrative Practice and Procedure (page images at HathiTrust)
Filed under: Drugs -- Research -- United States -- Finance The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1993. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust) The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1992. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust) Pricing of drugs codeveloped by federal laboratories and private companies : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, first session, Washington, DC, January 25, 1993. (U.S. G.P.O. :, 1993), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust) Legislative proposal to increase funding for medical research : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Fifth Congress, first session, special hearing. (U.S. G.P.O. :, 1998), by Health and Human Services United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor (page images at HathiTrust) Filed under: Drugs -- Research -- United States -- Information services Report of the Drug Control Research, Data, and Evaluation Committee. (Executive Office of the President, Office of National Drug Control Policy, 1999), by Data United States. Office of National Drug Control Policy. Drug Control Research (page images at HathiTrust) Report of the Drug Control Research, Data, and Evaluation Committee (Executive Office of the President, Office of National Drug Control Policy, 2003), by Data United States. Office of National Drug Control Policy. Drug Control Research (page images at HathiTrust) Filed under: Drugs -- Research -- United States -- PeriodicalsFiled under: Contraceptive drugs -- Research -- United StatesFiled under: Doping in sports -- Research -- United StatesFiled under: Drug control -- Research -- United StatesFiled under: Orphan drugs -- Research -- United States Treating rare and neglected pediatric diseases : promoting the development of new treatments and cures : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eleventh Congress, second session ... July 21, 2010. (U.S. G.P.O. :, 2012), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust) Filed under: Drugs -- Law and legislation -- Research -- United States Drug issues hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, October 1, 1987--Orphan Drug Amendments of 1987 (H.R. 3349), October 5, 1987--Generic Animal Drug and Patent Term Restoration Act (H.R. 3120), May 16, 1988--Consumer Product Safe Testing Act (H.R. 1635). (U.S. G.P.O., 1988), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust) Drug issues : hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, October 1, 1987--Orphan Drug Amendments of 1987 (H.R. 3349), October 5, 1987--Generic Animal Drug and Patent Term Restoration Act (H.R. 3120), May 16, 1988--Consumer Product Safe Testing Act (H.R. 1635). (U.S. G.P.O. :, 1988), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust) Filed under: Drugs -- Testing -- Research -- United StatesMore items available under broader and related terms at left. |